Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
about
Emerging approaches in Parkinson's disease - adjunctive role of safinamideAdjuvant therapies for Parkinson's disease: critical evaluation of safinamideTherapy for Parkinson's disease: what is in the pipeline?Inhibitors of MAO-A and MAO-B in Psychiatry and NeurologyNew treatments for the motor symptoms of Parkinson's disease.The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Recent advances in treating Parkinson's disease.Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacParkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease.Parkinson's disease: an update on pathogenesis and treatment.Therapeutic prospects for Parkinson disease.Current status of safinamide for the drug portfolio of Parkinson's disease therapy.Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Safinamide for the treatment of Parkinson's disease.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Safinamide for the treatment of Parkinson's disease.Improving L-dopa therapy: the development of enzyme inhibitors.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Safinamide: first global approval.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.Formulary Drug Review: Safinamide.Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence
P2860
Q26740905-62B44379-D13A-4185-8E55-A12AC19E3AF5Q26766289-E2F7D63E-5D53-4E82-9D7F-C1CEA20ADAF8Q26991826-CE80C1D9-3AC1-40BC-81C0-699D7DBDA7E2Q28069609-7135D3A6-5E0C-4782-B385-35FBC549D1D1Q34443682-DDA72C66-ED2E-46DE-9903-8BFF95598BC8Q34512544-253606E3-D5F3-4A14-96BB-3338C90A2006Q34554401-D162C57B-AA7B-44DB-9E6D-608DE13BBD3EQ34853030-473879D6-DED5-4D89-A26E-F9A5EB156B41Q35212961-78CC0592-8EFB-4CE5-95DD-BA3F190E3773Q36164724-C7EAB37B-918E-4241-BC6D-EB4BC3891878Q37303004-351BC5BE-C599-425C-AFF4-140CD998E2E7Q38099279-0BF59F69-7447-4C6E-90D7-D0E99E677752Q38137889-9272ABEF-75B7-45FF-B39D-DA9A9E268068Q38140018-0FD1D112-04C3-40B2-A716-1478A2252056Q38179453-BCCD3EB4-E4EF-455F-8B64-4625657C4236Q38197710-72D4664E-FC09-4B66-912B-3DA7F603E5A8Q38212033-8599DA67-4B4C-46AA-B15C-95FC8FBD36BCQ38258514-27C79676-984B-41F7-9728-520B8A16281BQ38261811-27B98C1A-43A7-4331-92B3-8052E9228E19Q38262418-062D942F-FE51-4100-836C-2044B146463CQ38410199-AD08531C-49DB-4DD7-B979-585AD4E8805CQ38478999-02F61581-A82B-40F6-899C-49B3FCB3B95DQ38545359-3CEEE65D-781E-4BED-88FE-7D9AC792E495Q38640108-1847F808-49CD-4271-8F81-CAF2E40C06D9Q38817972-09EABF4B-5223-4749-AA4E-620AA284A863Q42531922-9ABF8A9B-B7BA-4B86-A1B3-8F3033C25BEDQ49587005-A74212B7-F70E-4737-A1CA-0CA4C34DA046Q57074141-10972484-F654-44AB-99F2-A5DA100D0AA3
P2860
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term efficacy and safety ...... in early Parkinson's disease.
@en
Long-term efficacy and safety ...... in early Parkinson's disease.
@nl
type
label
Long-term efficacy and safety ...... in early Parkinson's disease.
@en
Long-term efficacy and safety ...... in early Parkinson's disease.
@nl
prefLabel
Long-term efficacy and safety ...... in early Parkinson's disease.
@en
Long-term efficacy and safety ...... in early Parkinson's disease.
@nl
P2093
P2860
P1476
Long-term efficacy and safety ...... in early Parkinson's disease.
@en
P2093
A H V Schapira
P Lorenzana
R Borgohain
R Giuliani
Study 017 Investigators
P2860
P304
P356
10.1111/J.1468-1331.2012.03840.X
P577
2012-09-12T00:00:00Z